Viking Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 28, 2017

Details of these presentations and panels are as follows:

•	Maxim Group Inaugural Healthcare Investor and Partnering Conference, Shanghai, China
	Panel: Chasing the Next Blockbuster
	Time/Date:	Monday, March 6 at 1:40 PM CST ARIVA.DE Börsen-Geflüster Kurse Viking Therapeutics Inc 67,30 € +0,33%
	Location:	The Park Hyatt Shanghai
	Presentation:
	Time/Date:	Monday, March 6 at 2:45 PM CST
	Location:	The Park Hyatt Shanghai
	Panel: Establishing POC Data for Unmet Medical Needs
	Time/Date:	Tuesday, March 7 at 3:20 PM CST
	Location:	The Park Hyatt Shanghai
•	29th Annual Roth Conference, Dana Point, California
	Time/Date:	Monday, March 13 at 7:00 AM PT
	Location:	Ritz Carlton Laguna Niguel
	Room:	Yellow – Salon 6

To access the live webcast of Viking's presentation at the 29^th Annual Roth Conference, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking also plans to initiate a proof-of-concept study of VK2809 in patients with glycogen storage disease type Ia.  The company is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-upcoming-investor-conferences-300414454.html

SOURCE Viking Therapeutics, Inc.